Background-In the Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial, women assigned to lasofoxifene 0.5 mg/d had a lower risk of major coronary heart disease (CHD) events and stroke, whereas women assigned to lasofoxifene 0.25 mg/d had a lower risk of stroke. Both doses of lasofoxifene increased the risk of venous thromboembolic events. In this report, we provide comprehensive cardiovascular end-point data, including component events comprising the composite end point of major CHD events, and evaluate whether the effect of lasofoxifene 0.5 mg/d is consistent across different categories of CHD risk. Methods and Results-In this study, 8556 women 59 to 80 years of age with osteoporosis received lasofoxifene 0.25 mg/d, lasofoxifene 0.5 mg/d, or placebo for 5 years. Cardiovascular events, including major CHD events, were prespecified secondary end points. Compared with placebo, lasofoxifene 0.5 mg/d reduced the risk of major CHD events 32% (hazard ratio, 0.68; 95% confidence interval, 0.50 to 0.93), including the risk of coronary revascularization (hazard ratio, 0.56, 95% confidence interval, 0.32 to 0.98). Reductions in risk of hospitalization for unstable angina (hazard ratio, 0.55; 95% confidence interval, 0.29 to 1.04) and diagnosis of new ischemic heart disease (hazard ratio, 0.52; 95% confidence interval, 0.26 to 1.04) nearly reached significance (Pϭ0.06 for both comparisons). Although both hazard ratios were Ͻ1.0, no significant effect of lasofoxifene at 0.5 mg/d was demonstrated for coronary death or nonfatal myocardial infarction. The reduction in CHD events with lasofoxifene 0.25 mg/d was not significant (hazard ratio, 0.76; 95% confidence interval, 0.56 to 1.03; Pϭ0.08). The effectiveness of lasofoxifene 0.5 mg/d in reducing CHD events was similar across strata of major cardiovascular risk factors. Conclusions-In postmenopausal women with osteoporosis, lasofoxifene 0.5 mg/d for 5 years reduced the risk of CHD events, regardless of the presence or absence of risk factors for cardiovascular disease. The significant reduction in risk of CHD events with lasofoxifene 0.5 mg/d was due primarily to lower risks of coronary revascularization procedures, hospitalization for unstable angina, and diagnosis of new ischemic heart disease. Clinical Trial Registration-URL: http://www.clinicaltrials.gov.
L asofoxifene is a selective estrogen receptor modulator (SERM) with high affinity and selectivity for estrogen receptors, leading to estrogen-agonist effects in some tissues and estrogen-antagonist effects in others. 1 Previous randomized trials of tamoxifen in postmenopausal women with breast cancer 2 and trials of raloxifene 3, 4 and lasofoxifene 5 in healthy postmenopausal women have found favorable changes in lipid levels with treatment. However, previous randomized trials of tamoxifen 6, 7 and raloxifene 8, 9 have reported no benefit on risk of coronary heart disease (CHD) events and an increased risk of venous thromboembolic events (VTEs). In addition, some evidence from randomized trials supports an increased risk of stroke with tamoxifen 6, 10 and fatal stroke with raloxifene. 9 
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The Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial was a randomized, double-blind, placebo-controlled trial in postmenopausal women with osteoporosis that was designed primarily to determine the effect of lasofoxifene (0.25 or 0.5 mg/d) on the incidence of nonvertebral fracture and estrogen receptor-positive breast cancer at 5 years. Cardiovascular disease (CVD) end points, including the risk of major CHD events (a composite end point), were secondary end points specified a priori. As previously reported, 11 treatment with lasofoxifene 0.5 mg/d for 5 years reduced the risk of fractures (nonvertebral and vertebral), estrogen receptor-positive breast cancer, major CHD events, and stroke, whereas these effects were not consistently demonstrated with lasofoxifene 0.25 mg/d. Both doses of lasofoxifene increased the risk of VTEs. In this article, we provide comprehensive results for cardiovascular end points (including the component events making up the composite end point of major CHD events). We also evaluate whether the effect of lasofoxifene 0.5 mg/d on risk of major CHD events was consistent across different categories of CHD risk.
Methods

Overview
PEARL was a global, multicenter, double-blind, placebo-controlled randomized trial. The study design, methods, and main trial results have been reported elsewhere. 11 The 2 primary objectives of PEARL were to determine the effects of 2 doses of lasofoxifene (0.25 and 0.5 mg/d) on the incidence of nonvertebral fractures and estrogen receptor-positive breast cancer through 5 years of follow-up. CVD events, including major CHD events, cerebrovascular events, hospitalization for cardiovascular events, VTEs, and CVD mortality, were secondary end points specified a priori.
A Scientific Advisory Committee of investigators was involved in protocol design, oversaw protocol execution, and planned analyses for manuscripts. One member (K.E.) wrote the prespecified analysis plan and first draft of this manuscript; the committee approved the manuscript for publication and vouches for its accuracy. The data were analyzed by the sponsor according to the analysis plan; the first author and writing group received all the analyses they requested.
The protocol was approved by the appropriate institutional review board for each clinical center. All women provided written informed consent. An independent data monitoring committee reviewed the unblinded data at least annually. The PEARL trial is registered at http://www.clinicaltrials.gov (NCT00141323).
Participants
Between November 2001 and February 2003, 8556 postmenopausal women were enrolled in PEARL at 113 sites in 32 countries. Eligible women were 60 to 80 years of age and had osteoporosis (bone mineral density T score of Ϫ2.5 or less [at least 2.5 SDs below average for healthy young women]) at the lumbar spine or femoral neck. Exclusion criteria, described in detail elsewhere, 11 included any past history of VTEs, spontaneous superficial thrombophlebitis in the previous 5 years, myocardial infarction (MI) or stroke within the previous 6 months, and atrial fibrillation treated with anticoagulation (eg, warfarin) therapy. To be eligible for randomization, women completed 2 screening visits and a 6-to 8-week single-blind, calcium/vitamin D supplement and placebo run-in period with at least 75% compliance with supplementation.
Treatment and Study Procedures
Using a permuted block algorithm with block size of 6, we randomly assigned eligible women to treatment groups in a 1:1:1 ratio of lasofoxifene 0.25 mg, lasofoxifene 0.5 mg, and identical-appearing placebo. Participants, investigators, laboratory and clinical center staff, and the sponsor were blinded to participants' treatment assignment. All participants received 1 g calcium and 400 to 800 IU vitamin D daily. After randomization, women attended clinic visits at 3 and 6 months and then every 6 months through 5 years. At each visit or telephone contact, adverse events and outcomes, including secondary end points, were ascertained.
Assessment of Risk Factors for CHD
Participants completed a questionnaire, were interviewed, and underwent a clinical examination at baseline. Information on smoking status, age at menopause, and previous use of hormone therapy was assessed by questionnaire. A medical history was obtained (diagnoses of hypertension, hyperlipidemia, diabetes mellitus, and CHD), and information on concomitant medication use, including statins, was collected. Blood pressure, weight, and height were measured at the baseline examination; weight and height were used to calculate body mass index. A resting 12-lead ECG was performed at baseline. Lipid levels (high-density lipoprotein [HDL] cholesterol and direct low-density lipoprotein [LDL] cholesterol) were measured at a central laboratory on baseline serum specimens with a Hitachi 911 analyzer (homogeneous enzymatic colorimetric assay, Roche Diagnostics, Indianapolis, Ind).
Ascertainment of Cardiovascular Outcomes
Reported CVD events and cause of death were adjudicated by a committee of 3 expert cardiologists blinded to treatment assignment who were not employees of the sponsor. The major cardiovascular end point (major CHD events) was defined as the first of any of the following events: coronary death (ie, sudden death, fatal MI, death resulting from ischemic heart disease [IHD], and death resulting from revascularization procedure), nonfatal MI, documented new IHD, hospitalization for unstable angina, or coronary revascularization procedure. MI was diagnosed if at least one of the following was present: ischemic symptoms and abnormal levels of cardiac enzymes, with or without new, equivocal changes on ECG; new evolving Q-wave pattern, with or without ischemic symptoms or abnormal levels of cardiac enzymes; ischemic symptoms and definite evolving ST-T abnormalities, with or without abnormal levels of cardiac enzymes; and new pathological Q waves, abnormal levels of cardiac enzymes, or definite evolving ST-T abnormalities, with abnormal levels of cardiac enzymes after invasive coronary procedures. New documented IHD in a woman not previously diagnosed with IHD was based on outpatient diagnoses of ECG evidence not present on baseline ECG, positive stress test, or new coronary angiographic findings of significant CHD. Hospitalization for unstable angina was defined as hospitalization for chest pain or anginal equivalent associated with evidence of myocardial ischemia (ECG evidence, positive stress test, or new coronary angiographic findings of significant CHD). Coronary revascularization procedures included percutaneous transluminal coronary angioplasty (with or without stenting), coronary artery bypass grafting, and cardiac transplantation.
Stroke was defined as the rapid onset of persistent brain deficit lasting Ͼ24 hours unless death intervened or there was a persistent lesion, consistent with the deficit by a neuroimaging scan. A transient ischemic attack was defined as documented focal neurological defect or typical symptoms persisting for Ͻ24 hours.
Hospitalization for a CVD event included hospitalizations for MI, angina, stroke, transient ischemic attack, congestive heart failure, peripheral arterial disease, and VTEs. VTEs included deep vein thrombosis (diagnosis based on imaging studies), pulmonary embolus (diagnosis based on imaging studies), and retinal vein thrombosis (diagnosis required ophthalmoscopic evidence). CVD mortality end points included coronary death and noncoronary cardiovascular death (eg, fatal stroke).
Statistical Analyses
All primary analyses used time-to-event methods and were based on the intention-to-treat principle. Rates of CVD outcomes were com-pared for each dose of lasofoxifene versus placebo through the use of Cox proportional-hazards models. Treatment effects were expressed using hazard ratios (HRs) and 95% confidence intervals (CIs). KaplanMeier curves were generated for the primary composite outcome major CHD events and its component end points. The log-rank test was performed to determine whether there were differences in the curves between each lasofoxifene group and the placebo group.
To test whether the effect of lasofoxifene 0.5 mg/d on risk of major CHD events was consistent across categories of risk, we compared the effect of lasofoxifene 0.5 mg/d on the incidence of major CHD events in risk groups defined at baseline by age (Ͻ70 versus Ն70 years), current smoking status, years since menopause (Յ10 versus Ͼ10), previous use of hormone therapy, statin use, hypertension, hyperlipidemia, diabetes mellitus, CHD, body mass index (Ͻ25 versus Ն25 kg/m 2 ), HDL cholesterol (Ͻ60 [median] versus Ն60 mg/dL), LDL cholesterol (Ͻ140 [median] versus Ն140 mg/dL), and Framingham CHD risk score 12 (Ͻ5.0%, 5% to 9.99%, Ն10%). To determine whether the effect of treatment with lasofoxifene 0.5 mg/d on risk of major CHD events varied by risk subgroup status, tests of interaction between treatment assignment and each risk factor were performed. Nominal P values are presented for the 27 subgroups examined. Thus, on average, 1 comparison would be expected to be statistically significant by chance alone at the Pϭ0.05 level.
The planned sample size of the trial (2500 participants per treatment group) was determined by the primary trial end points (nonvertebral fracture and estrogen receptor-positive breast cancer). On the basis of an underlying major CHD event rate of 1% per annum and actual sample size, the trial had 90% power to detect a 35% reduction in the time to first major CHD event with a 2-sided ␣ of 0.05.
Results
The PEARL trial randomized a total of 8556 participants; 2852 women were assigned to each of the following 3 treatment groups: lasofoxifene 0.25 mg/d, lasofoxifene 0.5 mg/d, and placebo ( Figure 1 ). The mean age of the participants was 67 years. Baseline characteristics, including cardiovascular risk factors, were equally distributed between treatment groups at baseline (Table 1) . Only 5% of women reported a personal history of CHD, and the median of the 10-year risk of developing CHD as calculated by the Framingham risk assessment tool was 7.0% (interquartile range, 4.7% to 10.0%). There was no evidence that discontinuation of study medication or termination of study participation varied by treatment group (Figure I in the online-only Data Supplement). In addition, among women who terminated participation, baseline CVD risk factor status, including Framingham CHD risk score, was similar between treatment groups.
Major CHD Events
During the median follow-up of 4.96 years, 95 women (3.3%) in the placebo group, 73 women (2.6%) in the lasofoxifene 0.25 mg/d group, and 65 women (2.3%) in the lasofoxifene 0.5 mg/d group experienced Ն1 major CHD event (Table 2) . Compared with placebo, lasofoxifene 0.5 mg/d reduced the risk of major CHD events by 32% (HR, 0.68; 95% CI, 0.50 to 0.93); the 24% reduction in the lasofoxifene 0.25 mg/d group did not reach significance (HR, 0.76; 95% CI, 0.56 to 1.03; Pϭ0.08). The cumulative incidence curves for first major CHD event by treatment group were similar for each of the lasofoxifene dose groups, and these curves appeared to separate from the curve for the placebo group by 2 years of treatment (Figure 2A ). The effectiveness of lasofoxifene 0.5 mg/d in reducing the risk of major CHD events was similar across strata of major cardiovascular risk factors, including history of CHD ( Figure  3) . The point estimates of risk within strata defined by baseline statin use suggested that the benefit of 0.5 mg/d in reducing risk of major CHD events might be greater among women not taking statins at baseline (P for interactionϭ0.03). However, the prevalence of baseline statin use was low (8%) and the 95% CI around the point estimate of risk was wide in this stratum. There was also some evidence that the relative benefit of lasofoxifene 0.5 mg/d might more pronounced among women with a body mass index Ͻ25 kg/m 2 compared with that among heavier women (P for interactionϭ0.01). Table 2 ). There was no evidence that treatment with Figure 4 ). There were 7 deaths attributed to pulmonary embolus reported by investigators (1 in the placebo group, 3 in the 0. Table 2 ). The lack of benefit of lasofoxifene in reducing cardiovascular hospitalizations appeared to be related primarily to the increased risk of VTEs with treatment (Table I in the online-only Data Supplement). There was no difference between the placebo and lasofoxifene 0.5 mg/d groups in rates of cardiovascular death, including noncoronary cardiovascular death (Table 2) . Although there was no significant difference in rate of cardiovascular death between lasofoxifene 0.25 mg/d and placebo, the rates of noncoronary cardiovascular death were higher in the 0.25 mg/d group (HR, 2.56; 95% CI, 1.07 to 6.13; Pϭ0.03), primarily because of fatal stroke (12 versus 5 cases).
Other Cardiovascular Events
Discussion
In older women with osteoporosis, treatment with lasofoxifene 0.5 mg/d for 5 years reduced the risk of CHD events regardless of the presence or absence of risk factors for CVD, decreased the risk of overall stroke, had no effect on hospitalization for cardiovascular events or cardiovascular mortality, and increased the risk of VTEs. Effects of lasofoxifene 0.25 mg/d on these outcomes were generally consistent with those of 0.5 mg/d, but the lower dose did not significantly reduce the risk of major CHD events.
The significant reduction in risk of major CHD events in women assigned to lasofoxifene 0.5 mg/d is in contrast to findings from previous SERM trials. Trials of tamoxifen in women at increased risk of breast cancer, 6,7 a meta-analysis of trials of tamoxifen in women with or at increased risk of breast cancer, 13 and a meta-analysis of trials of tamoxifen for primary breast cancer prevention 14 all reported no effect of therapy on incidence of MI. The apparent discrepancy in findings between lasofoxifene 0.5 mg/d and tamoxifen might, in part, reflect differences in study populations or adjudication of incident CHD end points. However, the Multiple Outcomes of Raloxifene Evaluation (MORE) trial 8 reported no effect of raloxifene on risk of CHD events (the definition of the composite end point was similar to that in PEARL) in women with osteoporosis like those enrolled in PEARL. A posthoc analysis of MORE did suggest a reduction in risk of combined coronary and cerebrovascular events with raloxifene treatment among the subgroup of women at increased CVD risk. However, these findings were not confirmed in the Raloxifene Use for The Heart (RUTH) trial, which enrolled women with or at high risk of CHD. 9 Tamoxifen, 2,15 raloxifene, 3, 4 and lasofoxifene 3, 11 all lower LDL cholesterol (with no effect on HDL cholesterol); the magnitude of the reduction appears greatest with lasofoxifene. Lasofoxifene 11, 16 and tamoxifen, 17 but not raloxifene, 18 reduce levels of C-reactive protein, and all 3 agents lower fibrinogen levels. 4, 15, 16 Thus, it is unlikely that the different 
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effects of SERMs on CHD events are explained entirely by differences in lipids, inflammatory markers, or hemostatic factors. It is possible that differences between SERMs on risk of CHD events might be at least partially explained by differences in affinity for estrogen receptors, receptor/ligand 3-dimensional conformation, gene expression, or half-life and tissue distribution. 1 The available trial data offer no apparent explanations for why lasofoxifene appears to have cardioprotective effects but the other SERMS do not.
Rates of each type of major CHD event, including coronary death and nonfatal MI, were lower in the lasofoxifene 0.5 mg/d group than in the placebo group, but the significant reduction in risk of major CHD events with lasofoxifene 0.5 mg/d at 5 years was due primarily to lower risks of coronary revascularization procedures, hospitalization for unstable angina, and diagnosis of new IHD. The effect of lasofoxifene 0.5 mg/d in reducing risk of major CHD events was generally consistent within categories of CHD risk defined by risk subgroups, including the estimated 10-year CHD risk. However, there was some evidence that the benefit of treatment might be most pronounced among women not taking statins and women of normal and lower body weight. These findings are in contrast to those for raloxifene 19 in that the lack of benefit of raloxifene in reducing CHD events in RUTH was consistent across categories based on statin use and body mass index. Because SERMs modulate the action of estradiol in many tissues by binding to the estrogen receptor and because endogenous estradiol levels are correlated with body weight, it is plausible that a woman's degree of adiposity might alter the effect of SERMs on risk of disease outcomes. The effect of lasofoxifene on the risk of CHD among women with higher and lower estradiol levels is unknown. It is also possible that this finding is due to chance.
The overall incidence of stroke was significantly reduced in both lasofoxifene groups, a finding that differs from those reported in other SERM trials. A large trial of tamoxifen in women at increased risk of breast cancer 6 and meta-analyses of trials of tamoxifen for breast cancer prevention and therapy 10, 13 found an increase in the overall risk of stroke with treatment. Although the MORE trial in osteoporotic women 8 and the RUTH trial 9 in women with or at increased risk of CHD reported no effect of raloxifene on the overall risk of stroke, raloxifene was associated with a significant increase in the risk of fatal stroke in the RUTH trial. In PEARL, we found no effect of treatment with lasofoxifene 0.5 mg/d on the risk of fatal stroke, but there was an increase (albeit not significant) in deaths caused by stroke in the 0.25 mg/d group. In agreement with the results of previous trials of SERMs, 6 -9 lasofoxifene treatment increased the risk of VTEs. The mechanisms underlying the consistent effects of SERMs on VTEs in contrast to their differing effects on CHD and stroke outcomes are unknown but may reflect differential binding and modulation of estrogen receptors at the tissue level.
Lasofoxifene at either dose had no effect on the risk of hospitalization for cardiovascular events or risk of CVD death. As previously reported, 11 lasofoxifene 0.5 mg/d had no effect on all-cause mortality. However, there was an unexplained increase in total mortality observed with lasofoxifene 0.25 mg/d (90 deaths in the 0.25 mg/d group versus 65 in the placebo group; Pϭ0.05). A biological rationale for the difference in effect of the 2 doses and a lack of dose-response effect on total mortality is unknown.
The PEARL trial has limitations. Although reductions in risk of CHD events and stroke with lasofoxifene 0.5 mg/d reached statistical significance and were similar in magnitude to those achieved with statin therapy for primary and secondary CHD prevention in women, 20, 21 the number of events was limited and multiple comparisons were performed. Participants in PEARL were selected on the basis of an increased risk of fracture as a result of low bone mineral density, not on the basis of their risk for CHD; the median estimated 10-year risk of CHD (7%) was somewhat lower than that calculated for women of similar age using population-based data. 12 Thus, these findings may not be generalizable to other groups of postmenopausal women. The primary cardiovascular end point, major CHD events, was a composite outcome for which some components had a greater influence on the overall estimate of effect than others. Data on the efficacy and safety of treatment with lasofoxifene 0.5 mg/d beyond 5 years are lacking. Finally, cardiovascular events were not primary outcomes in the PEARL trial but were prespecified adjudicated secondary end points. Clinical trials in postmenopausal women with or at increased risk of CVD are required to confirm these findings.
Conclusions
Treatment with lasofoxifene 0.5 mg/d for 5 years in postmenopausal women with osteoporosis reduced the risk of major CHD events and stroke but increased the risk of VTEs. The reduction in risk of CHD events with the 0.5 mg/d dose was consistent across categories of cardiovascular risk factors and appeared to be due primarily to lower risks of coronary revascularization procedures, hospitalization for unstable angina, and diagnosis of new IHD. Compared with other SERMS currently available to postmenopausal women, lasofoxifene 0.5 mg/d appears to have a favorable benefit-to-risk profile for cardiovascular events while also reducing the risk of fractures and estrogen receptor-positive breast cancer. Randomized trials of lasofoxifene in postmenopausal women at increased CVD risk are warranted.
